Merck & (MRK) 10-K Summary — Year Ended Dec 31, 2024
Merck is a pharmaceutical company that develops and commercializes medicines. Its financial performance improved in the latest year, with revenue growth and strong cash generation.
Key takeaway
Year ended Dec 31, 2024 · FY2025 10-K
Merck is a pharmaceutical company that develops and commercializes medicines. Its financial performance improved in the latest year, with revenue growth and strong cash generation.
Financial snapshot
Selected annual figures reported with the filing, shown separately from the narrative summary.
Annual revenue
$64.2B
Revenue reported for the fiscal year.
Operating income
n/a
Income from operations reported for the year.
Net income
$17.1B
Net income reported for the year.
Operating cash flow
$21.5B
Cash generated by operating activities.
Annual revenue trend
Reported annual revenue and its change from the preceding fiscal year.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2021 | $48.7B | n/a |
| Dec 31, 2022 | $59.3B | +21.7% |
| Dec 31, 2023 | $60.1B | +1.4% |
| Dec 31, 2024 | $64.2B | +6.7% |
Business overview
The company is primarily engaged in research, development, and commercialization of pharmaceutical products, supported by acquisitions and external alliances. It funds internal research and development, supports existing products, and prepares for new launches while returning cash to shareholders.
Financial performance
Revenue increased year over year, continuing a multi-year growth trend. Net income was substantial, and operating cash flow was strong, reflecting improved operating performance.
Material risks
The filing identifies risk factors but does not provide specific details in the supplied sections. These risks generally pertain to the company's operations, including competition, regulatory challenges, and execution of its strategy.
Liquidity and capital
The company maintains a strong financial profile, with operating cash flow serving as the primary funding source for operations, acquisitions, capital expenditures, dividends, and share repurchases. Cash flow from operations was robust in the latest period.
What to watch
Investors should monitor the progress and financial impact of significant collaborations, including milestone and continuation payments.